Refractory Clinical Trials in Beijing, Beijing Municipality
51 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 51 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Not Applicable
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital353 enrolled1 locationNCT06343090
Recruiting
Phase 1Phase 2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Not Applicable
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital213 enrolled1 locationNCT06389305
Recruiting
Phase 3
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.120 enrolled1 locationNCT06776952
Recruiting
Phase 2
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
B-cell Lymphoma Refractory
Daihong Liu10 enrolled1 locationNCT07321301
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1Phase 2
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 2
Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)
Peking University People's Hospital56 enrolled1 locationNCT06869265
Recruiting
Not Applicable
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL+1 more
Peking University People's Hospital130 enrolled1 locationNCT06581081
Recruiting
Phase 1Phase 2
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences20 enrolled1 locationNCT06834529
Recruiting
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253
Recruiting
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
Phase 2
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Minimal Residual DiseaseMyelodysplastic SyndromesRefractory Acute Myeloid Leukemia+1 more
Beijing 302 Hospital67 enrolled1 locationNCT06536959
Recruiting
Phase 2
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Chongqing Precision Biotech Co., Ltd100 enrolled10 locationsNCT05334823
Recruiting
Phase 1Phase 2
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT05896046